LLY stock sentiment todayEli Lilly and Company
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
LLY
Eli Lilly and CompanyA dominant leader in the weight-loss gold rush with a massive clinical pipeline, justifying its premium valuation despite recent volatility.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for LLY. Not financial advice.
Price · last 12 months
Gossip
Market narrative is fixated on the 'duopoly' in the GLP-1 space. While supply constraints remain a talking point, the focus has shifted toward expanded indications for Mounjaro/Zepbound (sleep apnea, heart failure) and the potential of their next-gen 'Triple G' pill, orforglipron.
- ·GLP-1 supply chain expansion
- ·Medicare coverage expansion for weight-loss drugs
- ·Alzheimer’s drug (Kisunla) market uptake
- ·Speculation on stock split timing
Financial
Revenue growth is explosive, driven by volume rather than just pricing. While trading at a high forward P/E compared to traditional pharma, LLY's margins are expanding as manufacturing scales.
- ·30%+ Revenue growth YoY
- ·Net debt-to-EBITDA remains manageable
- ·Industry-leading R&D spend as % of revenue
- ·Operating margins approaching 35-40%
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Compounding pharmacies producing cheaper generic versions of tirzepatide
- ·Pricing pressure from PBMs and government regulation
- ·High execution risk in massive manufacturing facility build-outs
Peer temperature
How direct competitors stack up against LLY right now.
- NEUTRALNVONovo Nordisk
COLDER — Facing tighter supply bottlenecks than LLY and lacks the diversified Alzheimer’s portfolio catalyst.
See full analysis → - HOTVKTXViking Therapeutics
HOTTER — Higher risk/reward profile as a buyout target with promising oral weight-loss data.
See full analysis → - COLDPFEPfizer
COLDER — Struggling with post-COVID revenue declines and a late start in the high-growth obesity market.
See full analysis →
- LLY+22.5%
- NVO+5.5%
- VKTX-16.3%
- PFE+7.0%
Analyst price target
Consensus average of 25 analysts · median 1,550.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.